BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2025 10:33:26 AM | Browse: 23 | Download: 65
 |
Received |
|
2024-07-05 07:31 |
|
Peer-Review Started |
|
2024-07-05 07:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-10-20 10:45 |
|
Revised |
|
2024-11-02 15:19 |
|
Second Decision |
|
2024-12-16 02:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-12-16 07:52 |
|
Articles in Press |
|
2024-12-16 07:52 |
|
Publication Fee Transferred |
|
2024-11-08 01:55 |
|
Edit the Manuscript by Language Editor |
|
2024-12-28 21:53 |
|
Typeset the Manuscript |
|
2025-01-22 03:32 |
|
Publish the Manuscript Online |
|
2025-02-14 10:33 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit11 gene-mutated gastrointestinal stromal tumors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hai-Tao Li, Yun-Yun Du, Zhen Huang, Jin-Jin Li and Jun Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. zjun2323@sina.cn |
| Key Words |
Gastrointestinal stromal tumor; C-kit 11; Imatinib; Plasma concentration; Second-line treatment |
| Core Tip |
This study showed that increasing the dosage of imatinib (IM) for patients with advanced gastrointestinal stromal tumors harboring c-kit exon 11 mutation who experienced failure of first-line IM treatment can prolong overall survival when the plasma concentration is < 1100 ng/mL; and switching to another tyrosine kinase inhibitor can improve the disease control rate and achieve longer progression-free survival when the plasma concentration is ≥ 1100 ng/mL. Therefore, IM plasma concentration may guide the decision-making for second-line treatment. |
| Publish Date |
2025-02-14 10:33 |
| Citation |
<p>Li HT, Du YY, Huang Z, Li JJ, Zhang J. Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit11 gene-mutated gastrointestinal stromal tumors. <i>World J Gastrointest Oncol</i> 2025; 17(3): 98746</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i3/98746.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i3.98746 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
